These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 32708981)

  • 21. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
    Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
    Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combination of High Dose Hypofractionated Radiotherapy with Anti-PD1 Single Dose Immunotherapy Leads to a Th1 Immune Activation Resulting in a Complete Clinical Response in a Melanoma Patient.
    Milhem C; Moralès O; Ingelaere C; Pasquier D; Mordon S; Mortier L; Mirabel X; Delhem N
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942768
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J
    JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A phase II trial of stereotactic body radiotherapy with concurrent anti-PD1 treatment in metastatic melanoma: evaluation of clinical and immunologic response.
    De Wolf K; Kruse V; Sundahl N; van Gele M; Chevolet I; Speeckaert R; Brochez L; Ost P
    J Transl Med; 2017 Jan; 15(1):21. PubMed ID: 28137295
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
    Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
    Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased serum CCL26 level is a potential biomarker for the effectiveness of anti-PD1 antibodies in patients with advanced melanoma.
    Fujimura T; Tanita K; Ohuchi K; Sato Y; Lyu C; Kambayashi Y; Fujisawa Y; Tanaka R; Hashimoto A; Aiba S
    Melanoma Res; 2020 Dec; 30(6):613-618. PubMed ID: 32658051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.
    Saung MT; Zheng L
    Ann Pancreat Cancer; 2019 Dec; 2():. PubMed ID: 32405624
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non-small cell lung cancer.
    Zhang W; Shi F; Kong Y; Li Y; Sheng C; Wang S; Wang Q
    Cancer Med; 2022 Feb; 11(3):676-691. PubMed ID: 34862763
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Zhang Q; Cheng L; Qin Y; Kong L; Shi X; Hu J; Li L; Ding Z; Wang T; Shen J; Yang Y; Yu L; Liu B; Liu C; Qian X
    Clin Transl Immunology; 2021; 10(10):e1347. PubMed ID: 34729183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Primary tumor characteristics and next-generation sequencing mutations as biomarkers for melanoma immunotherapy response.
    Loo K; Gauvin G; Soliman I; Renzetti M; Deng M; Ross E; Luo B; Wu H; Reddy S; Olszanski AJ; Farma JM
    Pigment Cell Melanoma Res; 2020 Nov; 33(6):878-888. PubMed ID: 32564504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients.
    Gide TN; Silva IP; Quek C; Ahmed T; Menzies AM; Carlino MS; Saw RPM; Thompson JF; Batten M; Long GV; Scolyer RA; Wilmott JS
    Oncoimmunology; 2020; 9(1):1659093. PubMed ID: 32002281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. How anti-PD1 treatments are changing the management of melanoma.
    Hersey P; Kakavand H; Wilmott J; van der Westhuizen A; Gallagher S; Gowrishankar K; Scolyer R
    Melanoma Manag; 2014 Nov; 1(2):165-172. PubMed ID: 30190821
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma.
    Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patterns of relapse and response to retreatment in patients with metastatic melanoma or renal cell carcinoma who responded to interleukin-2-based immunotherapy.
    Lee DS; White DE; Hurst R; Rosenberg SA; Yang JC
    Cancer J Sci Am; 1998; 4(2):86-93. PubMed ID: 9532410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An Engineered IL15 Cytokine Mutein Fused to an Anti-PD1 Improves Intratumoral T-cell Function and Antitumor Immunity.
    Xu Y; Carrascosa LC; Yeung YA; Chu ML; Yang W; Djuretic I; Pappas DC; Zeytounian J; Ge Z; de Ruiter V; Starbeck-Miller GR; Patterson J; Rigas D; Chen SH; Kraynov E; Boor PP; Noordam L; Doukas M; Tsao D; Ijzermans JN; Guo J; Grünhagen DJ; Erdmann J; Verheij J; van Royen ME; Doornebosch PG; Feldman R; Park T; Mahmoudi S; Dorywalska M; Ni I; Chin SM; Mistry T; Mosyak L; Lin L; Ching KA; Lindquist KC; Ji C; Londono LM; Kuang B; Rickert R; Kwekkeboom J; Sprengers D; Huang TH; Chaparro-Riggers J
    Cancer Immunol Res; 2021 Oct; 9(10):1141-1157. PubMed ID: 34376502
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma - results of a prospective biomarker study.
    Forschner A; Battke F; Hadaschik D; Schulze M; Weißgraeber S; Han CT; Kopp M; Frick M; Klumpp B; Tietze N; Amaral T; Martus P; Sinnberg T; Eigentler T; Keim U; Garbe C; Döcker D; Biskup S
    J Immunother Cancer; 2019 Jul; 7(1):180. PubMed ID: 31300034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
    Troiani T; Giunta EF; Tufano M; Vigorito V; Arrigo P; Argenziano G; Ciardiello F; Romano MF; Romano S
    Br J Cancer; 2020 Jun; 122(12):1782-1790. PubMed ID: 32317723
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
    Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
    JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma.
    Zhao CY; Hwang SJE; Anforth R; Carlos G; Chou S; Carlino M; Fernández-Peñas P
    J Immunother; 2018 Sep; 41(7):343-349. PubMed ID: 29939876
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.